Biostar Pharmaceuticals, Inc. to Establish a Call Center as Its New B2C Sales Platform

XIANYANG, China, Aug. 8, 2012 /PRNewswire-Asia-FirstCall/ -- Biostar Pharmaceuticals, Inc. (NASDAQ GM: BSPM) ("Biostar" or "the Company"), a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, today announced that it will establish a call center as its new business to customer ("B2C") sales platform.   

Within the next 30 days, the Company will open, staff and equip a call center in Xianyang.  Operators assigned to this call center are all professionally trained sales staff that will be mainly responsible for answering customer calls and accepting orders.

Ronghua Wang, Biostar's Chief Executive Officer and Chairman, commented, "Promptly after receiving the 'green-light' approval from Xianyang State Food and Drug Administration (SFDA) authorities to resume sales of gel capsule products, our management team met to design, develop and implement a plan to accelerate the recovery of the gel capsule segment of our business.  As previously announced, our employees are working overtime and we have added a second shift to ramp up production and handle expected increased customer demand going forward.  We also initiated an aggressive advertising campaign, including medical journals and heath magazines, to rebuild consumer and physician confidence in our products."

He added, "The establishment of the B2C call center adds a new dimension to our sales model as it is an innovative measure in the PRC pharmaceutical industry.  The call center will inform customers about drug promotions, introduce new drugs, take and handle order fulfillment.  The call center staff will also contact customers as the refill date approaches.  Additionally, in order to improve after-sale service, our trained call center personnel will gather customer feedback on its experience using our drugs and, if desired, also connect them with doctors for further consultation.  We believe these services should enhance customer confidence in and loyalty to our products.  We hope that this measure will provide an additional boost to the Company's sales efforts going forward."

About Biostar Pharmaceuticals, Inc. 

Biostar Pharmaceuticals, Inc., through its wholly owned subsidiary and controlled affiliate in China, develops, manufactures and markets pharmaceutical and health supplement products for a variety of diseases and conditions.  The Company's most popular product is its Xin Aoxing Oleanolic Acid Capsule, an over-the-counter ("OTC") medicine for chronic hepatitis B, a disease affecting approximately 10% of the Chinese population. For more information please visit:

Safe Harbor relating to the Forward-Looking Statements

Certain statements in this release concerning our future growth prospects are forward-looking statements, within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended, which involve a number of risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. The company uses words and phrases such as "guidance," "forecasted," "projects," "is expected," "remain confident," "will" and similar expressions to identify forward-looking statements in this press release, including forward-looking statements. Undue reliance should not be placed on forward-looking information. Forward-looking information is based on current expectations, estimates and projections that involve a number of risks, which could cause actual results to vary and in some instances to differ materially from those anticipated by Biostar and described in the forward-looking information contained in this news release. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding the Company's ability to complete the contemplated clinical trials and capitalize on such opportunities, the Company's ability to recover its sales and revenue for the gel capsule segment of its business, the state of consumer confidence and market demand or the Company's products, success of our investments, risks and uncertainties regarding fluctuations in earnings, our ability to sustain our previous levels of profitability including on account of our ability to manage growth, intense competition, wage increases in China, our ability to attract and retain highly skilled professionals, time and cost overruns on fixed-price, fixed-time frame contracts, client concentration, our ability to successfully complete and integrate potential acquisitions, withdrawal of governmental fiscal incentives, political instability and regional conflicts and legal restrictions on raising capital or acquiring companies outside China. Additional risks that could affect our future operating results are more fully described in our United States Securities and Exchange Commission filings including our most recent Annual Report on Form 10-K for the year ended December 31, 2011, and other subsequent filings. These filings are available at  We may, from time to time, make additional written and oral forward-looking statements, including statements contained in our filings with the Securities and Exchange Commission and our reports to shareholders. We do not undertake to update any forward-looking statements that may be made from time to time by or on our behalf.

For more information contact:  


Biostar Pharmaceuticals, Inc.                  

The Equity Group, Inc.

Zack Pan, CFO                        

Lena Cati

Tel: 405-996-8829                      

Tel: 212 836-9611

Email: [email protected]  

Email: [email protected]

SOURCE Biostar Pharmaceuticals, Inc.